playfreeslotswinrealmoney| GlaxoSmithKline (GSK.US), a new asthma drug, has made a breakthrough, with annual sales expected to peak at US$3.8 billion

Zhitong Financial APP learned thatPlayfreeslotswinrealmoney, GSK (GSK)Playfreeslotswinrealmoney.us)PlayfreeslotswinrealmoneyThe experimental drug depemokimab has achieved the main goal of reducing asthma attacks in recent clinical trials. This breakthrough has not only brought a new growth point for the company, but also is expected to become an important milestone in the treatment of asthma. GlaxoSmithKline estimates that annual sales of the drug could peak at 3 billion pounds.Playfreeslotswinrealmoney(.10 billion US dollars).

It is understood that in the study of eosinophilic asthma patients, depemokimab showed a "significant and practical significance" effect, this asthma is characterized by high levels of eosinophils, eosinophils are a kind of white blood cells.

The results came as GlaxoSmithKline increased its investment in its respiratory health portfolio, including the launch of the respiratory syncytial virus (RSV) vaccine Arexvy. In addition, the company bought Aiolos Bio, a maker of asthma drugs, earlier this year, valued at $1.4 billion.

Depemokimab is one of 12 major products GlaxoSmithKline plans to launch in 2025 and says it has the potential to become a major driver of growth by the end of the century. GlaxoSmithKline also said that depemokimab is expected to be the first approved ultra-long-acting biological agent, which is administered once every six months for patients with severe asthma.

Tony Wood, GlaxoSmithKline's chief scientific officer, said: "depemokimab, discovered by scientists at Stevenich, not only continues our deep tradition and leadership in respiratory medicine, but also has the potential to bring real change to the millions of people around the world who suffer from severe asthma every day."

Notably, GlaxoSmithKline raised its full-year profit guidance earlier this month and said sales in the first half of this year would be higher than in the second half because of strong demand for its respiratory virus and shingles vaccine.

In terms of the latest results, GlaxoSmithKline's Q1 revenue was 7.36 billion pounds ($9.18 billion), up 10 per cent year-on-year at fixed exchange rate (CER), higher than market expectations of 7.07 billion pounds, and earnings per share of 43.1p, also higher than market expectations of 37.3p.

The drugmaker now expects adjusted earnings per share to grow by 8 to 10 per cent in 2024, up from 6 to 9 per cent previously forecast. The company also expects revenue growth to reach the upper end of the forecast range of 5 to 7 per cent in 2024.

The strategic focus of Emma Walmsley, CEO of GlaxoSmithKline, is to strengthen the focus on vaccines and infectious disease drugs, and to shift their attention to HIV to long-term treatment and preventive treatment. The strategy paid off as the company prepares to launch 12 new products from 2025.